辅助生殖技术控制性卵巢刺激期间促血栓形成生物标志物的变化
该多中心观察性队列研究纳入2017—2019年接受辅助生殖技术的64例不孕女性,比较三种卵巢刺激方案对内源性凝血酶生成潜力的影响。结果显示激动剂联合hCG方案和拮抗剂联合hCG方案在触发后7天凝血酶生成潜力继续升高,而GnRH激动剂触发方案保持稳定,但后者仍存在高凝状态持续。
要点
- 三种方案在触发日凝血酶生成潜力均升高,触发后7天变化不同。
- 激动剂联合hCG和拮抗剂联合hCG方案触发后7天凝血酶生成潜力继续升高。
- GnRH激动剂触发方案触发后7天凝血酶生成潜力稳定,但高凝状态仍持续。
核心结论
- 激动剂联合hCG方案和拮抗剂联合hCG方案在触发后7天较高凝状态高于GnRH激动剂触发方案。
- GnRH激动剂触发后尽管雌二醇水平急剧下降,高凝状态仍持续存在。
- 作者认为这些发现可能支持在高血栓风险患者中使用GnRH激动剂触发方案,并提示凝血参数可能长时间受到干扰。
研究设计与样本
- 多中心观察性队列研究,纳入2017—2019年接受辅助生殖技术的不孕女性。
- 共64例女性,平均年龄37.8岁;其中24例接受激动剂联合hCG触发方案,16例接受拮抗剂联合hCG触发方案,24例接受GnRH激动剂触发方案。
- 主要结局为用校准自动凝血酶生成图评估的内源性凝血酶生成潜力,在基线(T1)、排卵触发日(T2)和触发后7天(T3)测量。
- 采用混合效应线性回归模型比较各组内源性凝血酶生成潜力的变化。
- 临床试验注册号:NCT04188444。
主要发现
- 各组内源性凝血酶生成潜力随时间的变化总体差异有统计学意义。
- T1时各组内源性凝血酶生成潜力值相似,T2时各组均升高。
- 各组T2至T3期间差异最大:激动剂联合hCG组内源性凝血酶生成潜力在T3继续升高(+110 nM/L × min),拮抗剂联合hCG组继续升高(+171 nM/L × min),GnRH激动剂触发组保持稳定(-2 nM/L × min)。
- GnRH激动剂触发组平均血清雌二醇水平在T2统计学上高于激动剂联合hCG组和拮抗剂联合hCG组,在T3低于这两组。
- 性激素结合球蛋白在T3持续升高,尽管雌二醇水平下降,尤其在GnRH激动剂触发组。
临床怎么用
- 作者认为这些发现可能支持在高血栓风险患者中使用GnRH激动剂触发方案。
- 作者指出凝血参数可能长时间受到干扰。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of 3 different ovarian stimulation protocols on surrogate biomarkers of coagulation. DESIGN: Observational multicenter cohort study. SETTING: The study was conducted in assisted reproductive technology (ART) units. PATIENTS: Infertile women undergoing ART in 2017-2019 were included. INTERVENTIONS: None. MAIN OUTCOME MEASURE(S): Our primary outcome was the endogenous thrombin potential (ETP) assessed by the calibrated automated thrombogram. The ETP was measured at baseline (T1), on the day of ovulation triggering (T2), and 7 days after triggering (T3). Three protocols were prescribed according to the standards used and without hormonal before treatment: agonist protocol with human chorionic gonadotropin (hCG) trigger (ag-hCG), antagonist protocol with hCG trigger (atg-hCG), or GnRH agonist trigger. The evolution of ETP was compared among groups using a mixed-effects linear regression model. RESULT(S): Sixty-four women with a mean age of 37.8 years participated in the study: of which 24, 16, 24 received ag-hCG, atg-hCG, and GnRH agonist triggers, respectively. As expected, the mean serum estradiol levels in GnRH agonist trigger were statistically higher at T2 and lower at T3 than that for both ag-hCG and atg-hCG. Overall, the ETP evolution over time was statistically different between the groups. Values were similar between groups at T1 and increased at T2 in each group. The greatest difference occurred between T2 and T3 in each group. The ETP continued to increase at T3 in ag-hCG (+110 nM/L × min) and atg-hCG (+171 nM/L × min), but it remained stable in GnRH agonist trigger (-2 nM/L × min). Sex hormone-binding globulin showed persistent increase at T3 despite the fall in estradiol levels, particularly in the GnRH agonist trigger group. CONCLUSION(S): The ag-hCG and atg-hCG groups were associated with a higher hypercoagulable state at T3 than the GnRH agonist trigger group. However, our results show the persistence of a hypercoagulable state after the GnRH agonist triggering despite a sharp drop in estradiol levels. These findings may support the use of GnRH agonist trigger protocol in patients with high thrombotic risk and gives new insight into the fact that coagulation parameters could be disturbed for long time periods. CLINICAL TRIAL REGISTRATION NUMBER: NCT04188444.
引用
- Hugon-Rodin J, Casini A, Bénard J, et al. Prothrombotic biomarkers during controlled ovarian stimulation for assisted reproductive technology. Fertil Steril. 2023. PMID: 36805437. doi:10.1016/j.fertnstert.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。